Heart rate variability in pulmonary vascular disease at altitude: a randomised trial

Joël J Herzig; Silvia Ulrich; Simon R Schneider; Julian Müller; Mona Lichtblau; Tanja L Ulrich; Meret Bauer; Michael Furian; Konrad E Bloch; Laura Mayer; Esther I Schwarz

doi:10.1183/23120541.00235-2024

Heart rate variability in pulmonary vascular disease at altitude: a randomised trial

ERJ Open Res. 2024 Oct 28;10(5):00235-2024. doi: 10.1183/23120541.00235-2024. eCollection 2024 Sep.

Authors

Joël J Herzig^{1

2}, Silvia Ulrich^{1

2}, Simon R Schneider¹, Julian Müller¹, Mona Lichtblau^{1

2}, Tanja L Ulrich¹, Meret Bauer¹, Michael Furian¹, Konrad E Bloch^{1

2}, Laura Mayer¹, Esther I Schwarz^{1

2}

Affiliations

¹ Department of Pulmonology, University Hospital Zurich (USZ), Zurich, Switzerland.
² University of Zurich, Zurich, Switzerland.

Abstract

Background: Hypoxia is a trigger for sympathetic activation and autonomic cardiovascular dysfunction. Pulmonary vascular disease (PVD) is associated with hypoxaemia, which increases with altitude. The aim was to investigate how exposure of patients with PVD to hypobaric hypoxia at altitude affects autonomic cardiovascular regulation.

Methods: In a randomised crossover study, patients with PVD were studied for 1 day and one night at an altitude of 2500 m (hypobaric hypoxia) and low altitude at 470 m in a random order. Outcomes were heart rate variability (HRV) in the time domain and in the frequency domain (low frequency (LF)/high frequency (HF) and LF/HF) and heart rate (HR) during day and night and baroreflex sensitivity (BRS).

Results: In 25 patients with PVD (72% pulmonary arterial hypertension and 28% distal chronic thromboembolic pulmonary hypertension; mean±sd age 60.7±13.6 years), exposure to altitude resulted in significant increases in awake HR by 9.4 bpm (95% confidence interval (CI) 6.3-12.4, p<0.001) and nocturnal HR by 9.0 bpm (95% CI 6.6-11.4, p<0.001) and significant changes in awake and particularly nocturnal HRV indicating decreasing parasympathetic and increasing sympathetic activity (change in daytime LF/HF 1.7 (95% CI 0.6-2.8), p=0.004; nocturnal LF/HF 1.9 (95% CI 0.3-3.4), p=0.022) and a significant decrease in BRS (-2.4·mmHg^-1 (95% CI -4.3- -0.4, p=0.024)).

Conclusion: Exposure of PVD patients to altitude resulted in a significant change in HRV indicating an increase in sympathetic activity and a decrease in BRS. The relative change in HRV at altitude was more pronounced during sleep.